Related Experiment Video
Updated: Dec 29, 2025
05:51
A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
Published on: March 17, 2023
2.2K
Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging
Shulei Zhu1, Yalei Li2, Yushu Huang1
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai, 200062, P. R. China. wlu@chem.ecnu.edu.cn.
Journal of Materials Chemistry. B
|February 11, 2020
Summary
Researchers developed a novel fluorescent probe (NP-001) for cancer-specific bioimaging. This probe targets heat shock protein 90 (HSP90) in tumors, showing potential for early diagnosis and targeted therapy.
Area of Science:
- Biomedical Engineering
- Molecular Imaging
- Cancer Research
Background:
- Cancer-specific bioimaging is crucial for fluorescence-guided tumor therapy.
- Developing targeted probes enhances diagnostic and therapeutic capabilities.
- Heat shock protein 90 (HSP90) is a validated target in cancer therapy due to its tumor selectivity.
Purpose of the Study:
- To establish a highly efficient tumor-targeting fluorescent probe (NP-001) for cancer-specific bioimaging.
- To evaluate the efficacy of NP-001 in inhibiting heat shock protein 90 (HSP90) and its potential for tumor therapy.
- To assess the safety and pharmacokinetic profile of NP-001 for clinical applications.
Main Methods:
- Synthesis of NP-001, integrating 4-hydroxy-1,8-naphthalimide with the HSP90 inhibitor NVP-AUY922.
- In vitro and ex vivo assays to evaluate cell proliferation, apoptosis, and HSP90 inhibition.
- Confocal laser scanning microscopy (CLSM) for cellular internalization studies.
- Pharmacokinetic studies and histological analysis for toxicity and retention time assessment.
Main Results:
- NP-001 effectively arrested tumor cell proliferation and induced apoptosis.
- The probe selectively inhibited HSP90 within tumor cells.
- CLSM confirmed selective internalization of NP-001 by tumor cells, enabling cancer-specific bioimaging.
- Pharmacokinetic studies showed prolonged retention time with no significant organ toxicity.
Conclusions:
- NP-001 demonstrates significant potential as a fluorescent probe for targeted tumor imaging.
- The probe's ability to inhibit HSP90 suggests therapeutic applications.
- NP-001 shows promise for early diagnosis of metastatic disease and targeted cancer therapy.
